As of Sep 02
| -0.03 / -1.33%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 3.57, with a high estimate of 4.66 and a low estimate of 2.49. The median estimate represents a +61.01% increase from the last price of 2.22.
The current consensus among 2 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.